Sufficiency of Single‐Arm Studies to Support Registration of Targeted Agents in Molecularly Selected Patients with Cancer: Lessons from the Clinical Development of Crizotinib-Reference-Cited by-同舟云学术

Sufficiency of Single‐Arm Studies to Support Registration of Targeted Agents in Molecularly Selected Patients with Cancer: Lessons from the Clinical Development of Crizotinib

Published:2016-03 Issue:2 Volume:9 Page:63-73
ISSN:1752-8054
Container-title:Clinical and Translational Science
language:en
Short-container-title:Clinical And Translational Science

Author:

Selaru P¹,Tang Y¹,Huang B²,Polli A³,Wilner KD¹,Donnelly E⁴,Cohen DP¹

Affiliation:

1. Pfizer Oncology La Jolla California USA

2. Pfizer Oncology Groton Connecticut USA

3. Pfizer Oncology Milan Italy

4. Pfizer Oncology Cambridge Massachusetts USA

Funder

Pfizer

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cts.12388

Reference59 articles.

1. The High Cost of Cancer Drugs and What We Can Do About It

2. Cancer Research UK.How long does it take for a new drug to go through clinical trials? (accessed 9 December 2014).

3. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma

4. An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic Mechanisms

5. Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Criteria for assessing evidence for biomarker-targeted therapies in rare cancers—an extrapolation framework;Therapeutic Advances in Medical Oncology;2024-01

2. Do Early Phase Oncology Trials Predict Clinical Efficacy in Subsequent Biomarker-Enriched Phase III Randomized Trials?;Targeted Oncology;2022-10-05

3. High-grade glioma therapy: adding flexibility in trial design to improve patient outcomes;Expert Review of Anticancer Therapy;2022-02-13

4. Speeding Access to Precision Oncology Drugs: How Are We Doing With Biomarker-Driven Drug Approvals?;Journal of the National Comprehensive Cancer Network;2020-01

5. Response Rates and Durations of Response for Biomarker-Based Cancer Drugs in Nonrandomized Versus Randomized Trials;Journal of the National Comprehensive Cancer Network;2020-01